Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 5:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–47 of 23 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Atherosclerotic Cardiovascular Disease (ASCVD) Clear all
Completed Not applicable Interventional

A Cross-sectional Study of Lipoprotein(a) Levels in Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD)

NCT05378529
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Lp(a) Screening
Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 85 Years
Enrollment
39,480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
113
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 97 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2025 · Synced Jul 21, 2026, 5:57 PM EDT
Completed Not applicable Interventional

Telehealth Group Counseling and Preventive Care for Women

NCT06404515
View directory record Official record
Conditions
ASCVD, NSTEMI, STEMI, Coronary Artery Disease, Acute Coronary Syndrome, Myocardial Infarction, Unstable Angina, Chest Pain
Interventions
Telehealth Group Counseling
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2025 · Synced Jul 21, 2026, 5:57 PM EDT
Recruiting Phase 3 Interventional

Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD

NCT06813911
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease (ASCVD)
Interventions
Pelacarsen, Placebo, Inclisiran
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
35
States / cities
Birmingham, Alabama • Sun City West, Arizona • Beverly Hills, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 21, 2026, 5:57 PM EDT
Completed No phase listed Observational

Alirocumab and Ischemic Risk in Atherosclerotic Cardiovascular Disease (ASCVD)

NCT07615179
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease Without Prior Ischemic Events
Interventions
Alirocumab, Comparator: No PCSK9i Therapy (either mAb or siRNA)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
4,545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jul 21, 2026, 5:57 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of DII235 in Adults With Elevated Lipoprotein(a)

NCT07235046
View directory record Official record
Conditions
Lipoprotein Disorder
Interventions
DII235, Saline
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
37
States / cities
Birmingham, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Jul 21, 2026, 5:57 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Test 2 Treat: Can we Improve the Testing and Treatment of High Cholesterol in Patients Who Have Been Hospitalized for a Cardiac Event by Providing Education to Doctors and Patients?

NCT06471036
View directory record Official record
Conditions
ASCVD, LDL-C
Interventions
Care Champion Intervention
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 21, 2026, 5:57 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

NCT06292013
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
Interventions
Lepodisiran Sodium, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
17,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
222
States / cities
Birmingham, Alabama • Daphne, Alabama • Dothan, Alabama + 171 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 21, 2026, 5:57 PM EDT
Recruiting Phase 3 Interventional

Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)

NCT07157774
View directory record Official record
Conditions
Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Interventions
Muvalaplin, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
10,450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
131
States / cities
Apache Junction, Arizona • Gilbert, Arizona • Phoenix, Arizona + 107 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 21, 2026, 5:57 PM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy

NCT03337308
View directory record Official record
Conditions
Hyperlipidemias
Interventions
Bempedoic Acid + Ezetimibe Fixed-Dose Combination, Bempedoic Acid, Ezetimibe, Placebos
Combination Product · Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Ames, Iowa • Nashua, New Hampshire • Statesville, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced Jul 21, 2026, 5:57 PM EDT
Active, not recruiting Phase 3 Interventional

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial

NCT05581303
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Placebo, Olpasiran
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 85 Years
Enrollment
7,297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
133
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 112 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jul 21, 2026, 5:57 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk

NCT02991118
View directory record Official record
Conditions
Hypercholesterolemia, Atherosclerotic Cardiovascular Disease
Interventions
bempedoic acid, placebo
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
779 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Clearwater, Florida • Georgetown, Texas
Source: ClinicalTrials.gov public record
Updated Apr 26, 2020 · Synced Jul 21, 2026, 5:57 PM EDT
Active, not recruiting Phase 3 Interventional

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

NCT06383390
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
Interventions
Retatrutide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
205
States / cities
Alabaster, Alabama • Birmingham, Alabama • Daphne, Alabama + 158 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 21, 2026, 5:57 PM EDT
Completed No phase listed Observational

A Real-world Study of Inclisiran Adherence, Treatment Patterns, Patient Characteristics, and Effectiveness in ASCVD Patients With Hypercholesterolemia, ASCVD-risk Equivalent Patients With Hypercholesterolemia and Familial Hypercholesterolemia

NCT06507852
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease, Hypercholesterolemia
Interventions
Not listed
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Timeline
2022 – 2023
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced Jul 21, 2026, 5:57 PM EDT
Active, not recruiting Phase 3 Interventional

A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event

NCT07000123
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
AZD0780, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
3,103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
101
States / cities
Huntsville, Alabama • Irondale, Alabama • Mobile, Alabama + 92 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 21, 2026, 5:57 PM EDT
Completed No phase listed Observational

Patient and Provider Assessment of Lipid Management Registry

NCT02341664
View directory record Official record
Conditions
Hyperlipidemia, Hypercholesterolemia, Cardiovascular Disease, Diabetes, Chronic Kidney Disease (CKD), Hypertension, Smoking, Myocardial Infarction (MI), Unstable Angina, Angina, Coronary Artery Disease (CAD), Stroke, Transient Ischemic Attack (TIA), Carotid Stenosis, Peripheral Arterial Disease, Atherosclerosis, Claudication
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
7,658 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
14
States / cities
Little Rock, Arkansas • San Pedro, California • Ventura, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2020 · Synced Jul 21, 2026, 5:57 PM EDT
Completed Phase 3 Interventional Results available

Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol

NCT03399370
View directory record Official record
Conditions
ASCVD, Elevated Cholesterol
Interventions
Inclisiran Sodium, Placebo
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
1,561 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
145
States / cities
Birmingham, Alabama • Foley, Alabama • Huntsville, Alabama + 110 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2020 · Synced Jul 21, 2026, 5:57 PM EDT
Active, not recruiting Phase 3 Interventional

Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

NCT05202509
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Obicetrapib, Placebo
Drug
Lead sponsor
NewAmsterdam Pharma
Industry
Eligibility
18 Years and older
Enrollment
9,541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
199
States / cities
Alexander City, Alabama • Birmingham, Alabama • Fairhope, Alabama + 161 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Jul 21, 2026, 5:57 PM EDT
Completed Phase 2 Interventional Results available

A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events

NCT05563246
View directory record Official record
Conditions
Lipoprotein Disorder
Interventions
LY3473329, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
40 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Baltimore, Maryland • Dorchester, Massachusetts • Lima, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Jul 21, 2026, 5:57 PM EDT
Recruiting Phase 2 Interventional

Efficacy, Safety, and PopPK Profile of ABP-745 in Patients With Atherosclerosis

NCT07303777
View directory record Official record
Conditions
Atherosclerosis Cardiovascular Disease, ASCVD, ASCVD Management
Interventions
ABP-745 Dose A, Placebo, ABP-745 Dose B, ABP-745 Dose C
Drug
Lead sponsor
Atom Therapeutics Co., Ltd
Industry
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Beverly Hills, California • San Diego, California • Torrance, California + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Jul 21, 2026, 5:57 PM EDT
Recruiting No phase listed Observational

The Coronary Artery Calcium and Troponins in Rheumatoid Arthritis (CAT-RA) Study

NCT07315997
View directory record Official record
Conditions
Rheumatoid Arthritis (RA, Atherosclerotic Cardiovascular Disease (ASCVD)
Interventions
high sensitivity cardiac troponin
Diagnostic Test
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
35 Years to 79 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 21, 2026, 5:57 PM EDT
Completed Not applicable Interventional

Notification of Incidental Coronary Artery Calcium in Patients With Atherosclerotic Cardiovascular Disease (NOTIFY-ASCVD)

NCT05858879
View directory record Official record
Conditions
ASCVD, Coronary Artery Calcification
Interventions
Notification of patients and clinicians
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 84 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Jul 21, 2026, 5:57 PM EDT
Terminated No phase listed Observational

The Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9 Inhibitors (cvMOBIUS)

NCT04197453
View directory record Official record
Conditions
ASCVD
Interventions
Not listed
Lead sponsor
Amgen
Industry
Eligibility
40 Years to 99 Years
Enrollment
752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
143
States / cities
Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 126 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Jul 21, 2026, 5:57 PM EDT
Recruiting Phase 2 Interventional

Phase 2 Study of Kylo-11 in ASCVD Patients With Elevated Lp(a)

NCT07327840
View directory record Official record
Conditions
Lipoprotein Disorder
Interventions
Kylo-11 or matched placebo
Drug
Lead sponsor
Kylonova (Xiamen) Biopharma co., LTD.
Industry
Eligibility
18 Years to 80 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
16
States / cities
Los Angeles, California • San Diego, California • Santa Maria, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jul 21, 2026, 5:57 PM EDT